Drugs / Osanetant
Osanetant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05607342 | Jan → Sep 2023 | prostate adenocarcinoma | University of Kansas Medical Center | Terminated | No outcome recorded |
| Phase 0 | NCT05647447 | Jan → Sep 2023 | prostate adenocarcinoma | University of Kansas Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osanetant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05607342 ↗ |
| Known as | SB-236984 | ChEMBL registry synonym — accepted as the source's own label CHEMBL346178 ↗ |
| Known as | SR-14280 | ChEMBL registry synonym — accepted as the source's own label CHEMBL346178 ↗ |
| Known as | SR-142801 | ChEMBL registry synonym — accepted as the source's own label CHEMBL346178 ↗ |
| Modality | Small molecule | — CHEMBL346178 ↗ |
| Route | Oral | “200mg twice daily, oral” NCT05607342 ↗ |